Neuroleptic malignant syndrome.
Yasugi
Shinji
S
Garg
Vikas
V
Been
Greg
G
Magoulas
Penny
P
D000328:Adult; D000077582:Amisulpride; D018692:Antimanic Agents / Q000009:adverse effects / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001714:Bipolar Disorder / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016651:Lithium Carbonate / Q000009:adverse effects / Q000627:therapeutic use; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis*; D012008:Recurrence; D012307:Risk Factors; D013469:Sulpiride / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
D018692:Antimanic Agents; D014150:Antipsychotic Agents; D016651:Lithium Carbonate; D013469:Sulpiride; D000077582:Amisulpride